Europe CAR-T Cell Therapy Market Size, Share, By Drug Type (Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others), By Indication (Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others), By End-Users (Hospitals, Cancer Research Centers, and Others) and By Country - Trends, Analysis and Forecast till 2034

Report Code: PMI541824 | Publish Date: July 2024 | No. of Pages: 126

Europe Car T Cell Therapy Market Overview

Europe CAR-T Cell Therapy Market was valued at USD 1.6 billion in 2024 and is s expected to reach USD 8.8 Billion by 2034 growing at a CAGR of 2.8%

The CAR-T cell therapy market in Europe is gaining significant traction, supported by strong regulatory frameworks and collaborative efforts in cancer research. European countries are increasingly adopting CAR-T cell therapies as part of their strategy to enhance cancer treatment and improve patient outcomes. The region is becoming a critical player in the global CAR-T cell therapy market, driven by a commitment to healthcare innovation and excellence.

Europe Car T Cell Therapy Market Dynamics

Key Drivers of Target Market:

Supportive Regulatory Environment

Europe benefits from a well-structured regulatory framework that facilitates the approval and adoption of innovative therapies like CAR-T cell therapy. The European Medicines Agency (EMA) has established processes that expedite the evaluation and approval of advanced therapies, thereby enhancing market accessibility. This supportive regulatory environment instills confidence among developers and investors, encouraging further research and development of CAR-T therapies in Europe. The EMA’s PRIME (Priority Medicines) scheme, for instance, offers enhanced support for the development of medicines that target unmet medical needs, such as CAR-T therapies. This initiative not only accelerates the approval process but also provides early and proactive support, ensuring that groundbreaking therapies reach patients more swiftly.

Growing Investment in Biotech and Healthcare

There is a significant increase in investment in the biotechnology and healthcare sectors across Europe. Public and private funding initiatives are driving the development and commercialization of CAR-T cell therapies. European governments and healthcare organizations are actively supporting research initiatives and infrastructure development, fostering an environment that promotes innovation. The European Investment Bank and various national funding bodies provide substantial financial support to biotech startups and research institutions engaged in CAR-T cell therapy development. This influx of investment is crucial in advancing CAR-T cell therapy technologies and ensuring their integration into mainstream cancer treatment protocols. Additionally, public-private partnerships are playing a pivotal role in bridging the gap between research and market application, thereby accelerating the translation of scientific discoveries into viable therapies

Restrains:

Complex Manufacturing Processes

One of the primary challenges facing the CAR-T cell therapy market in Europe is the complex and time-consuming manufacturing processes involved. Producing CAR-T cell therapies requires highly specialized facilities and expertise, as well as stringent quality control measures. Ensuring the consistency and scalability of these production processes while maintaining high standards is a significant challenge. These complexities can impact the availability and affordability of CAR-T cell therapies, potentially hindering market growth. The personalized nature of CAR-T cell therapy necessitates a tailored approach for each patient, which complicates the manufacturing logistics. Moreover, the stringent regulatory requirements for the production and quality assurance of CAR-T cells add layers of complexity to the process. Addressing these manufacturing challenges is essential for scaling up the production and making CAR-T therapies more accessible and cost-effective for a broader patient population. This may involve investing in advanced manufacturing technologies, streamlining processes, and enhancing collaboration across the supply chain to improve efficiency and reduce costs.

Europe Car T Cell Therapy Market Segmentation

The Market is segmented based on Drug Type, Indication, End-User and Country.

Europe CAR-T Cell Therapy Market Report Scope:

Attribute

Details

Market Size 2024

USD 1.6 Billion

Projected Market Size 2034

USD 8.8 Billion

CAGR Growth Rate

2.8%

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Drug Type - Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others

By Indication - Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others

By End User - Hospitals, Cancer Research Centers, and Others

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2023 to 2034. For the purpose of this study, has segmented the Europe CAR-T Cell Therapy Market report based on Drug Type, Indication, End User and Country:

Segmentation

By Drug Type:

  • Ciloleucel
  • Axicabtagene
  • Brexucabtagene Autoleucel
  • Tisagenlecleucel
  • Others    

By Indication:

  • Acute Lymphocyctic Leukemia
  • Lymphoma
  • Non-Hodgkin Leukemia
  • Others

By End User:

  • Hospitals
  • Cancer Research Centers
  • Others

By Country:

  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe

Europe Car T Cell Therapy Market Key Players

The key players operating the Europe CAR-T Cell Therapy Market includes, Bristol Myer Squibb, MERCK & CO. INC., PFIZER INC., Bluebird Bio-Inc., Novartis AG, Caribou Biosciences Inc., CELGENE CORPORATION, Sorrento Therapeutics Inc.

Europe Car T Cell Therapy Market Company Profile

  • Bristol Myer Squibb, Inc. *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • MERCK & CO. INC.
  • PFIZER INC.
  • Bluebird Bio-Inc.
  • Novartis AG
  • Caribou Biosciences Inc.
  • CELGENE CORPORATION, INC.
  • Sorrento Therapeutics Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Europe Car T Cell Therapy Market Table of Contents

Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

Market Preview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By End User
    • Market Snippet, By Country
  • Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Market Trends
  • Product Launch
  • Merger and Acquisitions
  • Impact Analysis
  • PEST Analysis
  • Porter’s Analysis

Market Segmentation, By Drug Type, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Ciloleucel
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Axicabtagene
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Brexucabtagene Autoleucel
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Tisagenlecleucel
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Indication, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Acute Lymphocyctic Leukemia
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Lymphoma
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Non-Hodgkin Leukemia
    • Overview

Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

  • Others
    • Overview

Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, End User, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Cancer Research Centers
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Country, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Country Trends
  • Europe
    • Market Size and Forecast (USD Bn), By Drug Type, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By Indication, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By End User, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
      • UK
      • Germany
      • France
      • Russia
      • Italy
      • Rest of Europe

Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Bristol Myer Squibb, Inc. *
    • MERCK & CO. INC.
    • PFIZER INC.
    • Bluebird Bio-Inc.
    • Novartis AG
    • Caribou Biosciences Inc.
    • CELGENE CORPORATION, INC.
    • Sorrento Therapeutics Inc.

The Last Word

  • Future Impact
  • About Us
  • Contact

FAQs

Europe CAR-T Cell Therapy Market is segmented into Drug Type, Indication, End User and Country.

Supportive Regulatory Environment and Growing Investment in Biotech and Healthcare.

By Country, the Europe CAR-T Cell Therapy Market is segmented into UK, Germany, France, Russia, Italy and Rest of Europe, Germany is expected to dominate the Market due to increase in Investment in Research and better healthcare infrastructure.

The key players operating the Europe CAR-T Cell Therapy Market includes, Bristol Myer Squibb, MERCK & CO. INC., PFIZER INC., Bluebird Bio-Inc., Novartis AG, Caribou Biosciences Inc., CELGENE CORPORATION, INC., Sorrento Therapeutics Inc.